BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 12688312)

  • 1. Preferentially expressed antigen of melanoma (PRAME) in the development of diagnostic and therapeutic methods for hematological malignancies.
    Matsushita M; Yamazaki R; Ikeda H; Kawakami Y
    Leuk Lymphoma; 2003 Mar; 44(3):439-44. PubMed ID: 12688312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells.
    Quintarelli C; Dotti G; Hasan ST; De Angelis B; Hoyos V; Errichiello S; Mims M; Luciano L; Shafer J; Leen AM; Heslop HE; Rooney CM; Pane F; Brenner MK; Savoldo B
    Blood; 2011 Mar; 117(12):3353-62. PubMed ID: 21278353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia.
    Quintarelli C; Dotti G; De Angelis B; Hoyos V; Mims M; Luciano L; Heslop HE; Rooney CM; Pane F; Savoldo B
    Blood; 2008 Sep; 112(5):1876-85. PubMed ID: 18591381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2'-Deoxycytidine.
    Yan M; Himoudi N; Basu BP; Wallace R; Poon E; Adams S; Hasan F; Xue SA; Wilson N; Dalgleish A; Williams O; Anderson J
    Cancer Immunol Immunother; 2011 Sep; 60(9):1243-55. PubMed ID: 21553146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PRAME mRNA levels in cases with acute leukemia: clinical importance and future prospects.
    Paydas S; Tanriverdi K; Yavuz S; Disel U; Baslamisli F; Burgut R
    Am J Hematol; 2005 Aug; 79(4):257-61. PubMed ID: 16044453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia.
    Matsushita M; Ikeda H; Kizaki M; Okamoto S; Ogasawara M; Ikeda Y; Kawakami Y
    Br J Haematol; 2001 Mar; 112(4):916-26. PubMed ID: 11298586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expression of PRAME gene in acute leukemia and its clinical significance].
    Zhu YL; Liu J; Zhu P; DU JW; Zhang Y; Gu JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Dec; 15(6):1144-9. PubMed ID: 18088454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia.
    Rezvani K; Yong AS; Tawab A; Jafarpour B; Eniafe R; Mielke S; Savani BN; Keyvanfar K; Li Y; Kurlander R; Barrett AJ
    Blood; 2009 Mar; 113(10):2245-55. PubMed ID: 18988867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preferentially Expressed Antigen of Melanoma (PRAME) and Wilms' Tumor 1 (WT 1) Genes Expression in Childhood Acute Lymphoblastic Leukemia, Prognostic Role and Correlation with Survival.
    Khateeb EE; Morgan D
    Open Access Maced J Med Sci; 2015 Mar; 3(1):57-62. PubMed ID: 27275197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine.
    Yao Y; Zhou J; Wang L; Gao X; Ning Q; Jiang M; Wang J; Wang L; Yu L
    PLoS One; 2013; 8(8):e70522. PubMed ID: 23940586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PRAME peptide-specific CD8
    Matko S; Manderla J; Bonsack M; Schmitz M; Bornhauser M; Tonn T; Odendahl M
    Eur J Immunol; 2018 Aug; 48(8):1400-1411. PubMed ID: 29738081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes.
    Brossart P; Schneider A; Dill P; Schammann T; Grünebach F; Wirths S; Kanz L; Bühring HJ; Brugger W
    Cancer Res; 2001 Sep; 61(18):6846-50. PubMed ID: 11559560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of novel HLA-restricted preferentially expressed antigen in melanoma peptides to facilitate off-the-shelf tumor-associated antigen-specific T-cell therapies.
    Stanojevic M; Hont AB; Geiger A; O'Brien S; Ulrey R; Grant M; Datar A; Lee PH; Lang H; Cruz CRY; Hanley PJ; Barrett AJ; Keller MD; Bollard CM
    Cytotherapy; 2021 Aug; 23(8):694-703. PubMed ID: 33832817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.
    Gezgin G; Luk SJ; Cao J; Dogrusöz M; van der Steen DM; Hagedoorn RS; Krijgsman D; van der Velden PA; Field MG; Luyten GPM; Szuhai K; Harbour JW; Jordanova ES; Heemskerk MHM; Jager MJ
    JAMA Ophthalmol; 2017 Jun; 135(6):541-549. PubMed ID: 28448663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of an epitope derived from CML66, a novel tumor-associated antigen expressed broadly in human leukemia, recognized by human leukocyte antigen-A*2402-restricted cytotoxic T lymphocytes.
    Suemori K; Fujiwara H; Ochi T; Azuma T; Yamanouchi J; Narumi H; Yakushijin Y; Hato T; Hasegawa H; Yasukawa M
    Cancer Sci; 2008 Jul; 99(7):1414-9. PubMed ID: 18422754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [PRAME mRNA expression in newly diagnosed acute myeloid leukemia patients and its application to monitoring minimal residual disease].
    Qin YZ; Li JL; Zhu HH; Li LD; Chang Y; Hao L; Wang YZ; Jiang B; Lu XJ; Liu YR; Huang XJ; Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jul; 29(7):441-5. PubMed ID: 19035174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preferentially Expressed Antigen in Melanoma (PRAME) and the PRAME Family of Leucine-Rich Repeat Proteins.
    Hermes N; Kewitz S; Staege MS
    Curr Cancer Drug Targets; 2016; 16(5):400-14. PubMed ID: 26694250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy.
    Griffioen M; Kessler JH; Borghi M; van Soest RA; van der Minne CE; Nouta J; van der Burg SH; Medema JP; Schrier PI; Falkenburg JH; Osanto S; Melief CJ
    Clin Cancer Res; 2006 May; 12(10):3130-6. PubMed ID: 16707612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression patterns of costimulatory molecules on cells derived from human hematological malignancies.
    Zheng Z; Takahashi M; Aoki S; Toba K; Liu A; Osman Y; Takahashi H; Tsukada N; Suzuki N; Nikkuni K; Furukawa T; Koike T; Aizawa Y
    J Exp Clin Cancer Res; 1998 Sep; 17(3):251-8. PubMed ID: 9894758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expression of PRAME gene in adult acute leukemia and its significance in prognosis].
    Zhou PY; Li WJ; Wei CX; Zhou Z
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Dec; 15(6):1177-81. PubMed ID: 18088461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.